S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:MOLN

Molecular Partners (MOLN) Stock Price, News & Analysis

$4.20
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$4.20
$4.20
50-Day Range
$3.73
$4.84
52-Week Range
$3.35
$7.32
Volume
168 shs
Average Volume
1,749 shs
Market Capitalization
$152.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Molecular Partners MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
7.1% Upside
$4.50 Price Target
Short Interest
Healthy
0.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Molecular Partners in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.32) to ($2.41) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.55 out of 5 stars

Medical Sector

885th out of 938 stocks

Biological Products, Except Diagnostic Industry

144th out of 148 stocks

MOLN stock logo

About Molecular Partners Stock (NASDAQ:MOLN)

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

MOLN Stock Price History

MOLN Stock News Headlines

Leerink Partners Keeps Their Hold Rating on Molecular Partners (MOLN)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Molecular Partners AG (6ML0.MU)
Molecular Partners AG ADR MOLN
See More Headlines
Receive MOLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:MOLN
Fax
N/A
Employees
167
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$4.50
Low Stock Price Target
$4.50
Potential Upside/Downside
+7.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-69,040,000.00
Net Margins
-885.11%
Pretax Margin
-880.66%

Debt

Sales & Book Value

Annual Sales
$7.84 million
Book Value
$5.41 per share

Miscellaneous

Free Float
34,198,000
Market Cap
$152.67 million
Optionable
Not Optionable
Beta
0.77
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Patrick Amstutz Ph.D. (Age 49)
    Co-Founder, CEO, Member of Management Board & Director
    Comp: $735.87k
  • Dr. Michael Tobias Stumpp Ph.D. (Age 52)
    Co-Founder, Executive VP of Projects & Member of Management Board
  • Mr. Robert Hendriks
    Senior VP of Finance
  • Mr. Alexander Zurcher (Age 49)
    COO & Member of Management Board
  • Ms. Renate Gloggner (Age 54)
    Executive VP of People & Community and Member of Management Board
  • Mr. Daniel Steiner Ph.D.
    Senior Vice President of Research
  • Mr. Seth D. Lewis
    Senior Vice President of Investor Relations, Communications & Strategy
  • Mr. Michael Pitzner
    General Counsel, Compliance Officer, Senior VP Legal & Business Development
  • Dr. Pamela A. Trail Ph.D. (Age 68)
    Strategic Consultant
  • Ms. Anne Goubier D.V.M.
    Ph.D., Senior Vice President of Biology

MOLN Stock Analysis - Frequently Asked Questions

Should I buy or sell Molecular Partners stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Molecular Partners in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MOLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOLN, but not buy additional shares or sell existing shares.
View MOLN analyst ratings
or view top-rated stocks.

What is Molecular Partners' stock price target for 2024?

1 equities research analysts have issued 12 month target prices for Molecular Partners' stock. Their MOLN share price targets range from $4.50 to $4.50. On average, they anticipate the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 7.1% from the stock's current price.
View analysts price targets for MOLN
or view top-rated stocks among Wall Street analysts.

How have MOLN shares performed in 2024?

Molecular Partners' stock was trading at $4.18 at the beginning of 2024. Since then, MOLN shares have increased by 0.5% and is now trading at $4.20.
View the best growth stocks for 2024 here
.

When is Molecular Partners' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our MOLN earnings forecast
.

When did Molecular Partners IPO?

Molecular Partners (MOLN) raised $81 million in an initial public offering on Wednesday, June 16th 2021. The company issued 3,000,000 shares at a price of $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager.

How do I buy shares of Molecular Partners?

Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MOLN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners